Wall Street brokerages expect Immatics (NASDAQ:IMTX – Get Rating) to announce earnings per share of $1.86 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Immatics’ earnings, with the highest EPS estimate coming in at $2.07 and the lowest estimate coming in at $1.65. Immatics posted earnings of ($0.41) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 553.7%. The firm is scheduled to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Immatics will report full-year earnings of ($0.21) per share for the current fiscal year, with EPS estimates ranging from ($1.91) to $0.72. For the next financial year, analysts anticipate that the business will post earnings of ($1.77) per share, with EPS estimates ranging from ($2.32) to ($1.54). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Immatics.
Immatics (NASDAQ:IMTX – Get Rating) last announced its quarterly earnings data on Wednesday, March 23rd. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of $1.94 by ($2.24). Immatics had a negative return on equity of 154.19% and a negative net margin of 260.05%. The firm had revenue of $17.99 million during the quarter, compared to the consensus estimate of $84.78 million.
A number of hedge funds have recently added to or reduced their stakes in IMTX. Alyeska Investment Group L.P. increased its stake in shares of Immatics by 1.6% in the 1st quarter. Alyeska Investment Group L.P. now owns 1,409,495 shares of the company’s stock valued at $11,262,000 after buying an additional 21,883 shares during the period. State Street Corp increased its stake in shares of Immatics by 3.7% in the 1st quarter. State Street Corp now owns 94,898 shares of the company’s stock valued at $758,000 after buying an additional 3,381 shares during the period. Silverarc Capital Management LLC increased its stake in shares of Immatics by 13.9% in the 1st quarter. Silverarc Capital Management LLC now owns 445,334 shares of the company’s stock valued at $3,558,000 after buying an additional 54,179 shares during the period. Renaissance Technologies LLC increased its stake in shares of Immatics by 17.5% in the 1st quarter. Renaissance Technologies LLC now owns 61,798 shares of the company’s stock valued at $494,000 after buying an additional 9,198 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in shares of Immatics in the 1st quarter valued at $84,000. 36.61% of the stock is owned by hedge funds and other institutional investors.
Shares of IMTX stock traded down $0.16 during mid-day trading on Friday, reaching $7.30. The stock had a trading volume of 64,363 shares, compared to its average volume of 145,763. The firm’s 50 day simple moving average is $7.78 and its 200 day simple moving average is $9.48. Immatics has a one year low of $5.75 and a one year high of $16.30. The firm has a market cap of $459.24 million, a PE ratio of -4.35 and a beta of 0.38.
Immatics Company Profile (Get Rating)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
- Get a free copy of the StockNews.com research report on Immatics (IMTX)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.